Welcome to our dedicated page for CG Oncology SEC filings (Ticker: CGON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Phase III trial protocols, viral oncology jargon, and complex collaboration terms make CG Oncology’s SEC documents daunting. Whether you’re asking, “CG Oncology SEC filings explained simply” or hunting for a single line on cash runway, the technical detail can feel impenetrable.
Stock Titan turns that problem on its head. Our AI reads every 10-K, 10-Q, and 8-K the moment it posts to EDGAR, then highlights exactly where cretostimogene grenadenorepvec trial data, dilution risks, or manufacturing updates appear. Need to trace “CG Oncology quarterly earnings report 10-Q filing” when revenue is still zero? We tag R&D spend trends automatically. Wondering about “CG Oncology insider trading Form 4 transactions”? Real-time alerts surface each “CG Oncology Form 4 insider transactions real-time” entry so you can monitor executive stock moves before pivotal readouts.
Our coverage spans every disclosure type investors care about:
- Annual insight: “CG Oncology annual report 10-K simplified” distills risk factors, cash burn, and clinical milestones.
- Quarterly checkpoints: “CG Oncology earnings report filing analysis” connects trial spend to upcoming catalysts.
- Material events: “CG Oncology 8-K material events explained” pinpoints FDA designations and partnership updates.
- Governance: “CG Oncology proxy statement executive compensation” extracts stock-based pay tied to milestone success.
With AI-powered summaries, expert commentary, and historical charts, understanding CG Oncology SEC documents with AI becomes routine. Stop scrolling through hundreds of pages; use targeted insights to compare segment spend, track “CG Oncology executive stock transactions Form 4,” and act quickly when new data drops. All filings, all in one place—updated in real time so you never miss a trial milestone again.
CG Oncology (CGON) Form 144: The filer notifies a proposed sale of 100,000 shares of common stock through Merrill Lynch on NASDAQ with an approximate sale date of 09/03/2025. The aggregate market value is reported as $2,746,000.00 and the company reports 76,247,581 shares outstanding, implying the filing relates to a transaction representing a known, disclosed portion of outstanding equity.
The securities were acquired on 01/25/2024 in a private placement from the Company and paid in cash the same day. No securities were reported sold by the person in the past three months. The filing includes the standard signature representation that the seller is not aware of undisclosed material adverse information.
CG Oncology, Inc. (CGON) reported a Form 144 notice indicating a proposed sale of 1,000 common shares by a person exercising stock options on 09/03/2025. The shares were acquired and paid for in cash on the same date through exercise of stock options from the issuer. The proposed sale lists Morgan Stanley Smith Barney LLC as the broker and an aggregate market value of $27,460 based on the filing. The filer also disclosed two prior 10b5-1 plan sales on 07/17/2025 totaling 2,000 shares with gross proceeds of $56,000. The form includes the standard representation that the seller is unaware of undisclosed material adverse information.
CG Oncology, Inc. reported consolidated cash, cash equivalents and marketable securities of approximately $661.1 million and working capital of approximately $642.6 million, giving the company an explicit runway the company says extends into the first half of 2028. The company recorded a net loss of $75.9 million for the six months ended June 30, 2025, compared with a $35.8 million loss in the prior-year period, driven by higher research and development spending of $58.8 million and increased general and administrative costs of $32.2 million during the six months.
The balance sheet shows marketable securities of $646.4 million and a $26.0 million note receivable. Significant corporate developments disclosed include an Open Market Sale Agreement for up to $250.0 million (no sales as of June 30, 2025), a July 20, 2025 conversion and consolidation of an SPV, and a July 29, 2025 jury verdict unanimously rejecting ANI Pharmaceuticals' unjust enrichment claims so no royalty or damages are due under the disputed agreement.
FAQ
What is the current stock price of CG Oncology (CGON)?
What is the market cap of CG Oncology (CGON)?
